Skip to main content
. 2021 May 15;10(5):585. doi: 10.3390/antibiotics10050585

Table 3.

Univariate and multivariate analysis of factors associated with clinical failure at seven days.

OR (95%CI) p-Value * Adjusted OR p-Value **
Sex, male 1.230 (0.626,2.415) 0.548 1.182 (0.501,2.785) 0.702
Age > 77 1.155 (0.886,1.505) 0.286 1.129 (0.856,1.487) 0.388
Infectious diseases intervention 1.676 (0.891,3.154) 0.109
Pharmacy intervention 1.683 (0.681,4.161) 0.259
Previous antibiotic 1.314 (0.700,2.465) 0.396 1.763 (0.756,4.114) 0.189
Immunosuppressive treatment 2.001 (1.052,3.805) 0.034
Urinary catheterization 0.505 (0.159,1.609) 0.248
Other catheters 0.157 (0.020,1.248) 0.080
Previous urological manipulation 0.280 (0.092,0.851) 0.025
Urological pathology 0.543 (0.270,1.089) 0.086
History of recurrent UTIs 1.092 (0.572,2.084) 0.790
Diabetes 0.679 (0.360,1.280) 0.231
Urological neoplasms 0.176 (0.051,0.609) 0.006
McCabe–Jackson Index > 2 0.899 (0.684,1.181) 0.446 1.108 (0.848,1.447) 0.451
Charlson Comobilidity Index > 5.8 1.062 (0.862,1.308) 0.571 1.695 (0.921,3.120) 0.090
Bacteremia 1.936 (1.006,3.724) 0.048 2.412 (0.351,16.538) 0.370
Cystitis 1.018 (0.485,2.138) 0.962 1.656 (0.562,4.877) 0.360
Pyelonephritis 0.410 (0.192,0.875) 0.021 0.782 (0.246,2.487) 0.678
Prostatitis 0 (0,0) 0.999
Confusion syndrome associated with UTIs 2.215 (1.142,4.296) 0.019 5.155 (1.670,15.906) 0.004
Sepsis 2.275 (1.163,4.451) 0.016 3.758 (0.519,27.208) 0.190
Shock 3.964 (0.705,22.306) 0.118 7.239 (1.008,51.983) 0.049
ESBL 2.645 (1.376,5.084) 0.004 2.622 (1.086,6.328) 0.032
Time to adequate treatment 1.359 (1.092,1.692) 0.006 1.364 (1.059,1.755) 0.016
Appropriate empirical treatment 0.217 (0.106,0.443) <0.001
Duration of hospital treatment 1.285 (1.161,1.422) <0.001
CA-UTI 0.997 (0.528,1.881) 0.993

* Univariate analysis: Student’s t-test or Mann–Whitney U used for comparing quantitative variables. The Chi-square test was used for comparing qualitative variables. ** Multivariate analysis: binary logistic regression through the forward stepwise approach; ESBL: extended spectrum betalactamases; CA-UTI: Community-Acquired Urinary Tract Infection; OR: odds ratio.